# Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Source: https://onco.cc/trials/nct05294731/  
OnCo record `nct05294731` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BGB-16673 in hodgkin lymphoma and non-hodgkin lymphoma, run by BeiGene, now recruiting.

## Summary

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader is a phase 1/2 interventional study registered as NCT05294731 by BeiGene, with 146 participants planned, started 2022-05-06 and due to reach its primary completion in 2029-01-31. Interventions recorded: BGB-16673. Conditions listed: B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05294731
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
- Sponsor: BeiGene
- Enrolled: 146

## Sources

- ClinicalTrials.gov NCT05294731: https://clinicaltrials.gov/study/NCT05294731

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [BGB-16673](https://onco.cc/drugs/bgb-16673/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct05294731.json